Clinical Trial Update: A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing palbociclib in well/moderately differentiated metastatic pancreatic neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Cancer
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Pancreatic Neuroendocrine Cancer | Phase 2 | Status: COMPLETED